Recently, we reported a novel function for C4b-binding protein (C4BP) in inhibiting the toll-like receptor (TLR)1/2 response by interacting with TLR2. TLRs share a common structure; hence, we examined the effect of C4BP on activation of other TLRs-TLR4 and TLR3. The results of immunoprecipitation assays suggest that C4BP interacts with TLR4/MD-2 but not TLR3. C4BP inhibits TLR4/MD-2-mediated, but not TLR3-mediated, proinflammatory cytokine production and nuclear factor (NF)-jB signaling. C4BP-deficient mice show increased interleukin (IL)-6 production in response to the TLR4/MD-2 ligand. A competition assay revealed that C4BP prevents an interaction between TLR4/MD-2 and its ligand. These findings indicate that C4BP binds to cell surface TLRs and inhibits the TLR-TLR ligand interaction, thereby inhibiting TLR activation.
Toll-like receptors (TLRs) are type I transmembrane glycoproteins and play a crucial role in innate and adaptive immunities by recognizing diverse pathogenderived molecules. TLR1/TLR2, TLR2/TLR6, and TLR4/MD-2 localize to the cell surface and recognize microbial membrane lipids, such as Pam3CSK4 (TLR1/2) and lipopolysaccharide (LPS; TLR4/MD-2). Conversely, TLR3, TLR7, TLR8, and TLR9 localize to intracellular organelles and recognize microbial nucleic acids, such as poly(I:C) (TLR3) [1] [2] [3] . Binding of ligands to the extracellular domains of TLRs causes rearrangement of the receptor complexes [4, 5] , triggering an immune response. TLRs are important for tissue protection against pathogens, but an exaggerated response can be harmful because TLR activation by its ligands results in the production of proinflammatory cytokines, such as tumor necrosis factor (TNF)-a and interleukin (IL)-8. Therefore, modulating cytokine overproduction may attenuate inflammation.
C4b-binding protein (C4BP) was first identified as a fluid phase inhibitor of the classical and lectin complement pathways [6] and continuously prevents immunoreactions from the host tissue in the complement pathway. C4BP also has many other roles, such as B-cell activation [7] , regulation of blood coagulation [8] , and removal of apoptotic cells [9] . C4BP is synthesized in the liver [10] , and 200 lgÁmL À1 C4BP is contained in the human plasma in steady-state [11] . Furthermore, C4BP is classified as an acute-phase reactant because its level is elevated (up to 400%)
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during inflammation [6, 12] . Therefore, C4BP may be important for regulating inflammatory processes.
We recently reported a novel activity for C4BP in inhibiting the TLR1/2 response. C4BP binds to TLR2 and inhibits the binding of Pam3CSK4 to TLR1/2, thereby inhibiting Pam3CSK4-driven signaling [13] . The TLRs share a common structural framework in their extracellular ligand-binding domains [14] . This raises the possibility that C4BP may inhibit other TLR responses. Therefore, in the present study, we examined the effect of C4BP on the response of TLR4/MD-2 and TLR3.
Materials and methods

Reagents and plasmids
Lipid A Re595 and LPS from Escherichia coli O55:B5 were purchased from SIGMA (St. Louis, MO, USA). High molecular weight Poly(I:C) was purchased from InvivoGen (San Diego, CA, USA). Human IL-8 ELISA kit was purchased from BioLegend (San Diego, CA, USA). Mouse IL-6 and TNF-a ELISA kits were purchased from eBioscience (San Diego, CA, USA).
The cDNA-encoding mouse TLR4-GFP, mouse MD-2-Flag-His, mouse TLR3-GFP, and mouse C4BP-2HA was cloned into pCAGGS or pMXpuro (pCAGGS-TLR4-GFP, pCAGGS-MD-2-FH, pCAGGS-TLR3-GFP, and pMXpuro-C4BP-2HA).
Cells and mice
HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS and penicillin-streptomycin-glutamine. HEK293 cells stably expressing mouse TLR4, mouse MD-2, and mouse CD14 (HEK293-TLR4/MD-2/CD14), and those stably expressing mouse TLR3 (HEK293-TLR3) were purchased from InvivoGen. These HEK293 cells were cultured according to the manufacturer's instructions. RAW264.7 cells were cultured in DMEM containing 10% FBS and penicillin-streptomycin-glutamine. RAW264.7 cells stably expressing mouse C4BP (RAW-C4BP) and control cells (RAW-vec) were established by PLAT-E retroviral expression system using pMXpuro-C4BP-2HA or pMXpuro. These RAW264.7 cells were cultured in complete DMEM supplemented with 1 lgÁmL À1 puromycin. C57BL/6 C4BP-deficient mice were provided by MI Nonaka [15] .
Transfection
For transient C4BP expression, cells, such as HEK293T, HEK293-TLR4/MD-2/CD14, and HEK293-TLR3, cultured in a six-well plate or a 10-cm dish were transfected with 1.5 lg or 10 lg of pMXpuro-mC4BP-2HA, respectively, using polyethylenimine 'Max' (Cosmo Bio, Tokyo, Japan). In case of control, cells were transfected with empty pMXpuro. For analysis of interactions between C4BP and TLR4/MD-2 or TLR3, HEK293T cells in a six-well plate were transfected with 750 ng pCAGGS-TLR4-GFP + 300 ng pCAGGS-MD-2-FH or 750 ng pCAGGS-TLR3-GFP, together with 750 ng pMXpuro-C4BP-2HA using FuGENE HD (Promega, Madison, WI, USA). The total amount of transfected DNA was kept constant by including the appropriate amount of the empty pCAGGS or pMXpuro. The cells and supernatant were harvested 2 days post transfection.
Flow cytometry
For cell surface staining (TLR4/MD-2, TLR4, and CD14), cells were fixed using 1% paraformaldehyde (PFA) for 5 min at 25°C. For permeabilized staining (TLR3), cells were fixed using 1% PFA and permeabilized using 0.5% Triton X-100 for 10 min at 4°C. These cells were incubated with biotinylated anti-TLR4-MD-2 complex monoclonal antibody (mAb; MTS510) [16] 
Western blot analysis
Samples were resolved using 8% or 4-15% SDS/PAGE and then electroblotted onto a membrane filter (Immobilon-P; Millipore, Billerica, MA, USA). The membrane was blocked in TBST containing 3% skim milk for 15 min and incubated overnight at 4°C with biotin-anti-HA mAb (3F10; Roche Diagnostics), anti-mouse MD-2 rabbit pAb [18] , anti-GFP rabbit pAb (MBL), anti-TLR4 rat mAb (MT439) [19] , anti-TLR3 rabbit mAb (M-300; Santa Cruz, Dallas, TX, USA), anti-nuclear factor (NF)-jB p65 rabbit mAb (Cell Signaling, Beverly, MA, USA), and anti-phospho-NF-jB p65 rabbit mAb (Cell Signaling). The membrane was then incubated at room temperature for 1 h with HRP-conjugated streptavidin (GE Healthcare, Little Chalfont, UK), anti-rabbit IgG pAb (BD Biosciences or Cell Signaling), or anti-rat IgG pAb (Santa Cruz). Immunoreactive bands were visualized using the enhanced chemiluminescence substrate (GE Healthcare) and an LAS4000 imaging system (GE Healthcare). Band intensity was quantified by IMAGEQUANT TL software (GE Healthcare).
Exogenous addition of C4BP
HEK293T cells were transfected with pMXpuro-mC4BP-2HA or pMXpuro. At 2 days post transfection, the C4BP-containing or control culture supernatant (C4BP sup. or control sup.) was collected and 0.25 mL of the supernatant was added into HEK293-TLR4/MD-2/CD14, HEK293-TLR3, or RAW264.7 cells in 0.25 mL of culture medium in a 24-well plate (final concentration: 50%). After 2 h, these cells were stimulated with the indicated amount of Lipid A or poly(I:C) for 24 h, respectively.
Detection of LPS binding
HEK293-TLR4/MD-2/CD14 cells were transfected with the pMXpuro-mC4BP-2HA or pMXpuro. HEK293T cells were used as the negative control cell line for HEK293-TLR4/ MD-2/CD14 cells. These cells (2 9 10 6 ) were incubated with 50 lgÁmL À1 biotinylated LPS (InvivoGen) for 15 min at 37°C. Cells were then washed with cold PBS and fixed using 1% PFA followed by incubation with APC-conjugated streptavidin (BioLegend) for 15 min at 4°C. The stained cells were examined by flow cytometry.
Statistical analysis
Student's t-test was used to evaluate the significance of difference between groups. A value of P < 0.05 was considered statistically significant. All data are presented as the mean AE SD.
Results
C4BP inhibits TLR4/MD-2-mediated IL-8 production
To examine the inhibitory effect of C4BP on other TLR responses, the effect of C4BP on TLR4/MD-2-and TLR3-mediated IL-8 production was analyzed using TLR4/MD-2/CD14-and TLR3-expressing HEK293 cells, respectively. Stimulation with Lipid A, which is the biologically active part of LPS, resulted in increased IL-8 production, but C4BP expression significantly suppressed the response of HEK293-TLR4/ MD-2/CD14 cells to Lipid A (Fig. 1A upper ). These results indicate that C4BP inhibits TLR4/MD-2 response, but not TLR3 response.
C4BP interacts with TLR4/MD-2
Recently, we demonstrated that interaction between C4BP and TLR1/2 is important for the inhibition of TLR1/2 activity [13] . Thus, the interaction between C4BP and TLR4/MD-2 or TLR3 was examined by immunoprecipitation assay. HEK293T cells were transfected with the plasmids encoding TLR4-GFP, MD-2-FH, TLR3-GFP, or C4BP-2HA. These cells were lysed and subjected to immunoprecipitation with anti-GFP or anti-HA antibody. As shown in Fig. 2A , C4BP-2HA was coimmunoprecipitated with TLR4-GFP, and both TLR4-GFP and MD-2-FH were coimmunoprecipitated with C4BP-2HA, indicating that C4BP interacts with TLR4/MD-2. Additionally, the interaction between C4BP and endogenous TLR4 or TLR3 was examined using C4BP-expressing RAW264.7 cells. As shown in Fig. 2B , C4BP-2HA was coimmunoprecipitated with endogenous TLR4, but not with endogenous TLR3. These results suggest that the inhibitory effect of C4BP against the TLR4/MD-2 response is consistent with its binding ability as well as its effect against the TLR1/2 response described previously.
Exogenous C4BP exhibits similar inhibitory activity against TLR4/MD-2 activation As C4BP is a soluble protein, the inhibitory activity of exogenous C4BP against TLR4/MD-2-or TLR3-mediated IL-8 production was examined. As shown in Fig. 3A, C4BP -expressing or empty vector-transfected HEK293T cells were cultured and their supernatants were collected. C4BP-containing or control supernatant (C4BP sup. or control sup.) was added to the HEK293-TLR4/MD-2/CD14 cells exogenously, and then the cells were stimulated with Lipid A. By the addition of the C4BP sup, Lipid A-driven IL-8 production was significantly reduced in HEK293-TLR4/ MD-2/CD14 cells (Fig. 3B upper panel) . On the contrary, no significant difference in IL-8 production was observed by the addition of C4BP sup. in HEK293-TLR3 cells (Fig. 3B lower panel) . Additionally, the effect of exogenous C4BP in mouse macrophage RAW264.7 cells, which express TLR4, MD-2, and TLR3 endogenously, was examined. As shown in Fig. 3C , Lipid A-driven, but not poly(I:C)-driven, TNF-a production was significantly reduced by addition of the C4BP sup. Similar inhibitory activities were observed in case of IL-6 production (Fig. S2) . These results are in agreement with the inhibition observed by coexpression of C4BP, suggesting that exogenous C4BP is sufficient for inhibition of the TLR4/MD-2 response and does not affect the TLR3 response.
Furthermore, the effects of exogenous C4BP on Lipid A-or Poly(I:C)-driven signaling were examined. NF-jB is an important transcription factor that induces proinflammatory cytokines, such as IL-8 and TNF-a. Stimulation of TLR4/MD-2 or TLR3 leads to phosphorylation of the p65 subunit of NF-jB thereby facilitating transcriptional activity. As shown in Fig. 4 , phosphorylation of NF-jB p65 in response to Lipid A, but not in response to Poly(I:C), was significantly inhibited by addition of C4BP sup. These results suggest that exogenous C4BP inhibits TLR4/MD-2 signaling. The results of this and our recent study suggest that C4BP targets common pathways between the TLR4/ MD-2-and TLR1/2-dependent pathways. TLR1/2 and TLR4/MD-2 are localized on the cell surface to recognize pathogen-associated molecular patterns (PAMPs), whereas TLR3 is localized in intracellular organelles. Therefore, C4BP may only affect TLRs localized on the cell surface.
C4BP-deficient mice showed increased IL-6 production in response to LPS
To confirm the inhibitory activity of C4BP, the responsiveness of C4BP-deficient mice to Lipid A was examined. LPS was administered to mice and the serum IL-6 production was analyzed. As shown in Fig. 5 , serum IL-6 levels were significantly increased in C4BP-deficient mice, indicating that C4BP inhibits LPS-driven proinflammatory cytokine production not only in vitro but also in vivo.
C4BP inhibits the binding of LPS to TLR4/MD-2
Toll-like receptor activation is triggered by binding of ligand to TLRs. The TLRs form dimers when the TLR ligand is bound, thereby activating TLR downstream signaling pathways. Our recent study provided evidence that C4BP inhibits TLR1/2-ligand interactions thereby inhibiting the TLR1/2 response. Thus, the ability of C4BP to block interactions between TLR4/MD-2 and its ligand was assessed by flow cytometric analysis using biotin-labeled LPS. As shown in Fig. 6A , bound LPS was detected in HEK293-TLR4/ MD-2/CD14 cells transfected with empty vector and treated with LPS. When expressed with C4BP, the bound LPS was significantly reduced, suggesting that C4BP inhibits the binding of LPS to TLR4/MD-2. Next, the inhibition of binding of anti-TLR4/MD-2 mAb (MTS510), which recognizes the LPS-binding site on the TLR4 extracellular domain and MD-2 complex, was assessed to evaluate the utilization of TLR4 by C4BP (Fig. 6B) . . These cells were stimulated with 100 ng/ mL Lipid A (A) or 25 lg/mL Poly(I:C) (B) for 15, 30, or 60 min, and lysed in Laemmli sample buffer. These lysates were subjected to western blot analysis using anti-NF-jB p65 mAb or antiphospho-NF-jB p65 mAb (upper panel). Phosphorylation levels are expressed as fold increase over those of unstimulated cells (*P < 0.05, **P < 0.001, vs. control sup; lower panel).
Taken together, C4BP blocks the binding of LPS to TLR4/MD-2 by interacting with the LPS-binding site on TLR4/MD-2 at the cell surface, thereby preventing the activation of TLR4/MD-2 downstream signaling pathways (Fig. 7) .
Discussion
The present study provides several lines of evidence that C4BP targets the LPS-TLR4/MD-2 interaction for the impairment of TLR4/MD-2 activation-induced IL-8 production. First, C4BP binds to TLR4/MD-2. Second, C4BP exhibits inhibitory activity against TLR4/MD-2 activation in vitro and in vivo. Third, C4BP inhibits the interaction between LPS and TLR4/ MD-2. Fourth, C4BP masks the binding site of LPS on TLR4/MD-2. From these results, we concluded that C4BP inhibits the binding of LPS to TLR4/MD-2 through an interaction with TLR4/MD-2 that blocks initiation of TLR4/MD-2 activation-induced IL-8 production at the cell surface.
In addition to inhibitory activity against the TLR4/ MD-2 response as well as the TLR1/2 response, we revealed a C4BP-binding site on TLR4 using two distinct mAbs against TLR4-Sa15-21 and MTS510. Sa15-21 is able to detect TLR4 alone, while MTS510 is able to detect TLR4 only when MD-2 was coexpressed [20] . Furthermore, Sa15-21 does not compete with LPS, while MTS510 competes with LPS [16] . Because LPS binds to both TLR4 and MD-2 [5] , MTS510 is thought to recognize LPS-binding site on the TLR4-MD-2 complex. C4BP competed with MTS510 ( Fig. 6B) , suggesting that C4BP probably binds to the LPS-binding site on the TLR4/MD-2.
We observed that C4BP-2HA was coimmunoprecipitated with TLR3-GFP to a lesser extent ( Fig. 2A) . TLR3 is expressed and activated in endosomes; however, it is reported that TLR3 is also expressed on the cell surface in several cell lines [17, 21] . Indeed, the cell line we used also expressed a measurable amount of TLR3 on the cell surface (data not shown). As a soluble protein, C4BP might bind to the remaining TLR3 on the cell surface, but not to TLR3 in the endosomes; therefore, C4BP does not inhibit TLR3 activity.
Our study reports a novel inhibitory activity of C4BP against the TLR4/MD-2 response and further reveals that a similar inhibitory activity of C4BP is not observed against the TLR3 response. TLR2 and TLR4/ MD-2 localize on the cell surface, while TLR3 localizes in the intracellular organelles. As C4BP is a soluble protein, these findings suggest that C4BP may target common pathways among cell surface TLRs and play an important role in modulating the response of cell surface TLRs. The TLRs share a common structural framework in their extracellular ligand-binding domains [14] ; moreover, as TLR2 and TLR4 play a similar role in some diseases, such as sepsis [22] and Alzheimer's disease [23] , it is possible that common regions of cell surface TLRs are involved in the underlying mechanism. The detailed investigation of the binding sites involved in the interaction between C4BP and TLRs might be important for immunomodulatory therapy.
Unregulated TLR activation participates in the onset of numerous diseases. Therefore, regulating the TLR activation is important for preventing inflammatory diseases. For example, IL-8 is known to play a role in the development of airway inflammation when it is produced in excess by overactivation of TLR2 and TLR4, while A20, an NF-jB inhibitor, negatively regulates development of airway inflammation by inhibiting the activation of TLR2 and TLR4 [24] . Both our previous and current studies showed that C4BP inhibits TLR1/2 and TLR4/MD-2 activity. Additionally, C4BP is elevated during inflammation. Therefore, C4BP might play a vital role in controlling the immune response induced by cell surface TLRs.
In summary, we demonstrated that C4BP binds to TLR4/MD-2 and inhibits the binding of LPS to TLR4/MD-2, thereby inhibiting LPS-driven signaling. Establishing the structural requirements necessary for the inhibitory activities of C4BP might lead to the development of novel therapeutic strategies to treat TLR-related inflammatory diseases. 
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